Cambridge Nutritional Sciences plc (AIM:CNSL)
1.550
0.00 (0.00%)
Oct 30, 2026, 8:45 AM GMT
AIM:CNSL Revenue
In the fiscal year ending March 31, 2026, Cambridge Nutritional Sciences had annual revenue of 6.98M GBP, down -16.27%. Cambridge Nutritional Sciences had revenue of 3.11M in the half year ending March 31, 2026. That makes Cambridge Nutritional Sciences the 37,661st largest company in the world by revenue and 735th in the United Kingdom.
Revenue
6.98M
Revenue Growth
-16.27%
P/S Ratio
0.53
Revenue / Employee
82.06K
Employees
85
Market Cap
3.69M
Revenue by Geography
- United Kingdom 1.66M 23.8%
- Rest of Europe 1.55M 22.2%
- Asia and The Far East 1.46M 20.9%
- Americas 998.00K 14.3%
- India 845.00K 12.1%
- Africa and The Middle East 468.00K 6.7%
Fiscal year ended Mar 31, 2026 See the full AIM:CNSL breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.98M | -1.36M | -16.27% |
| Mar 31, 2025 | 8.33M | -1.44M | -14.77% |
| Mar 31, 2024 | 9.77M | 2.23M | 29.53% |
| Mar 31, 2023 | 7.55M | -993.00K | -11.63% |
| Mar 31, 2022 | 8.54M | 1.72M | 25.28% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 46.25B |
| GSK plc | 33.54B |
| Haleon | 11.15B |
| Smith & Nephew | 4.77B |
| Surgical Innovations Group | 11.48M |
| Fortis Frontier | 3.22M |
| GENinCode | 2.60M |
| Futura Medical | 2.32M |